Mirgi (Ethinylestradiol, Etonogestrel)

The two hormones work together to suppress the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) from the pituitary gland, preventing ovulation. Etonogestrel also thickens cervical mucus, making it difficult for sperm to travel, while both agents induce endometrial changes that reduce the chance of implantation.

The dosing regimen for Mirgi is determined by the prescribing clinician. Typically, the vaginal ring is inserted and left in place for three weeks, followed by a ring‑free week, but the exact schedule and any adjustments are individualized based on the patient’s medical history and therapeutic goals.

Mirgi is intended for use only by women who are not pregnant. If pregnancy occurs, the ring should be removed immediately and an alternative contraceptive method considered. Limited data are available on use during breastfeeding; clinicians usually advise against use until after the postpartum period unless the benefits outweigh potential risks.

To request Mirgi, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both Mirgi and oral combined pills contain ethinylestradiol and a progestogen, but Mirgi delivers the hormones continuously via a vaginal ring, eliminating the need for daily dosing. This can improve adherence and provide more stable hormone levels, while oral pills require daily intake and may have more variable absorption.

Mirgi should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the product away from extreme heat or humidity, and do not expose the ring to chemicals or sharp objects that could damage its integrity.

Mirgi is a flexible vaginal ring that is inserted into the upper vagina by the user or a healthcare professional. Once placed, it remains in situ for three weeks, continuously releasing hormones, after which it is removed and a new ring is inserted following a one‑week ring‑free interval.

The most serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe allergic reactions, hepatic adenoma, and significant hypertension. Patients should be educated to seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe headache, visual changes, or signs of an allergic reaction.

Mirgi is contraindicated in women with a history of thromboembolic disorders, active or past breast cancer, uncontrolled hypertension, severe liver disease, known or suspected pregnancy, and in smokers over the age of 35. It should also be avoided in individuals with known hypersensitivity to any component of the ring.